(Q36366495)

13 August 2017

1 reference

title

Kidney cancer: identification of novel targets for therapy (English)

1 reference

13 August 2017

1 reference

R H Weiss

1

1 reference

13 August 2017

P-Y Lin

series ordinal

2

1 reference

13 August 2017

language of work or name

English

0 references

publication date

1 January 2006

1 reference

13 August 2017

1 reference

13 August 2017

volume

69

1 reference

13 August 2017

issue

2

1 reference

13 August 2017

page(s)

224-232

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.ki.5000065

13 August 2017

exact match

0 references

cites work

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Rising incidence of renal cell cancer in the United States

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

RENAL CELL CARCINOMA: PROGNOSTIC SIGNIFICANCE OF INCIDENTALLY DETECTED TUMORS

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Renal cell carcinoma as an incidental finding

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Paraneoplastic Signs and Symptoms of Renal Cell Carcinoma: Implications for Prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Renal neoplasm in acquired cystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Delayed CT to evaluate renal masses incidentally discovered at contrast-enhanced CT: demonstration of vascularity with deenhancement

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Small renal masses: assessment of lesion characterization and vascularity on dynamic contrast-enhanced MR imaging with fat suppression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Ultrasound of renal tumors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

The genetic basis of cancer of the kidney

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Mutations of the VHL tumour suppressor gene in renal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Genetic basis of cancer of the kidney: disease-specific approaches to therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

The VHL tumour-suppressor gene paradigm

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Polycythemia: mechanisms and management

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

von Hippel-Lindau disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

What Is the Evidence That Tumors Are Angiogenesis Dependent?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

The implications of angiogenesis for the biology and therapy of cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Proliferation, cell cycle and apoptosis in cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Regression of metastatic renal cell carcinoma after cytoreductive nephrectomy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Interleukin-2 based immunotherapy for metastatic renal cell carcinoma with the kidney in place

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

The natural history of small renal masses

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

A randomized prospective assessment of recombinant leukocyte A human interferon with or without aspirin in advanced renal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Phase II study of alpha interferon on renal cell carcinoma. Summary of three collaborative trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

The impact of interleukin-2 on survival in renal cancer: a multivariate analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Prognostic factors for survival with gemcitabine plus 5-fluorouracil based regimens for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Current treatment of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Phase II trial of arsenic trioxide in patients with metastatic renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Three molecularly targeted drugs tested in kidney cancer clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Phase II trial of ZD1839 (IRESSA) in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Will mTOR inhibitors make it as cancer drugs?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Mechanism of action of rapamycin: new insights into the regulation of G1-phase progression in eukaryotic cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Loss of tumor suppressor protein PTEN during renal carcinogenesis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Expression of PTEN in renal cell carcinoma and its relation to tumor behavior and growth

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Rapamycin is an effective inhibitor of human renal cancer metastasis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

p21Waf1/Cip1 as a therapeutic target in breast and other cancers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Wortmannin inhibits the growth of mammary tumors despite the existence of a novel wortmannin-insensitive phosphatidylinositol-3-kinase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

HIF-1α mRNA and protein upregulation involves Rho GTPase expression during hypoxia in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitor, fluvastatin, as a novel agent for prophylaxis of renal cancer metastasis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: mechanism and therapeutic implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Inhibitory effect of YC-1 on the hypoxic induction of erythropoietin and vascular endothelial growth factor in Hep3B cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Oncogenic functions of tumour suppressor p21(Waf1/Cip1/Sdi1): association with cell senescence and tumour-promoting activities of stromal fibroblasts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

The role of apoptosis in cancer development and treatment response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Targeting of adenovirus to human renal cell carcinoma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Kinase inhibition with BAY 43-9006 in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase III outcomes.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.KI.5000065

7 January 2021

Identifiers

DOI

10.1038/SJ.KI.5000065

1 reference

13 August 2017

1 reference